PMID: 7515580May 1, 1994Paper

Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors

The American Journal of Physiology
K F RabeH Magnussen

Abstract

The effects of the nonselective phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the selective PDE inhibitors motapizone (type III), rolipram (type IV), zardaverine (type III/IV), and zaprinast (type V and I) on prostaglandin F2 alpha (PFG2 alpha)-induced tone in human pulmonary arteries was investigated. Relaxation was achieved by IBMX [concentration eliciting 50% of maximum response (EC50): 11.3 microM, n = 10], motapizone (EC50:3.0 microM, n = 7), zardaverine (EC50: 3.2 microM, n = 9), and zaprinast (EC50: 31.8 microM, n = 6), whereas rolipram was almost ineffective. The combination of motapizone and zaprinast (10 microM) was the most effective relaxant with supra-additive relaxation and a motapizone EC50 of 575 nM. Biochemical studies revealed the presence of the PDE isozymes I, III, IV and V in the cytosolic and particulate phases of arterial homogenates; PDE II was not detectable. Partial inhibition of adenosine 3',5'-cyclic monophosphate (cAMP)-hydrolyzing PDE activity was achieved with rolipram (26 +/- 2.2%) or motapizone (60 +/- 5.4%), whereas there was almost complete inhibition of total PDE activity with zardaverine (81 +/- 2.0%) or the combination of motapizone and rolipram (82 +/- 2.3%). Inh...Continue Reading

Citations

Aug 25, 2000·American Journal of Physiology. Lung Cellular and Molecular Physiology·H SchütteF Grimminger
Aug 21, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·Inja LimGianrico Farrugia
Nov 15, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·Oleg V EvgenovFumito Ichinose
Mar 27, 2007·American Journal of Physiology. Lung Cellular and Molecular Physiology·William J PerkinsKeith A Jones
Apr 9, 2005·American Journal of Respiratory and Critical Care Medicine·John WhartonMartin R Wilkins
Dec 21, 2000·American Journal of Physiology. Heart and Circulatory Physiology·R H SteinhornJ R Fineman
Sep 21, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Peter G PhillipsNicholas W Morrell
Oct 4, 2003·American Journal of Respiratory and Critical Care Medicine·Takefumi ItohHiroshi Kimura
Apr 5, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Siobhán B TarpeyMary I Townsley
Nov 8, 2001·American Journal of Physiology. Cell Physiology·K D KeefJ Zhong
May 25, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Olivier PauvertJean-Pierre Savineau
Nov 13, 2001·American Journal of Physiology. Lung Cellular and Molecular Physiology·R T SchermulyD Walmrath
Feb 13, 2001·American Journal of Physiology. Lung Cellular and Molecular Physiology·M Oka
Feb 1, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·B LarrueL Storme

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.